{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:11:29Z","timestamp":1790914289848,"version":"4.1.0"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010905","name":"Illumina","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010905","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Urol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tumor genomic profiling using liquid biopsies offers a minimally invasive alternative to tissue biopsy-based approach, with advantages in accessibility, tumor heterogeneity representation, and repeatability. While established in metastatic prostate cancer, its feasibility in localized disease remains unclear due to low ctDNA levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We evaluated the feasibility and performance of tissue and liquid-based genomic profiling in patients with high-risk localized prostate cancer enrolled in a phase 2 neoadjuvant trial. Genomic DNA from formalin-fixed paraffin-embedded (FFPE) tissue and cell-free DNA from plasma were analyzed using Illumina TruSight Oncology 500 panels and DRAGEN\u2122 pipelines, with in-house filtering of artifacts and germline variants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 22 FFPE tissue biopsies, only 54.5% (12\/22) yielded usable data, with failures due to low DNA quality or quantity. All 27 plasma samples (100%) were successfully sequenced, despite low ctDNA levels. Both approaches identified an average of 3.5 genomic variants per sample, including alterations in\n                      <jats:italic>SPOP<\/jats:italic>\n                      ,\n                      <jats:italic>ATRX<\/jats:italic>\n                      ,\n                      <jats:italic>ATM<\/jats:italic>\n                      , and\n                      <jats:italic>ARID1B<\/jats:italic>\n                      . Liquid-based genomic profiling achieved superior coverage and depth, enabling sensitive detection of low-frequency mutations. Concordance analysis was limited by the small number of matched samples (\n                      <jats:italic>n<\/jats:italic>\n                      = 4).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Liquid-based genomic profiling is feasible and achieved high sequencing success rates in high-risk localized prostate cancer. Although concordance analysis was limited, plasma-based profiling showed robust sequencing performance and detected biologically relevant alterations. These findings support liquid biopsy as a complementary approach for molecular characterization, particularly when tissue samples are limited or of suboptimal quality. Larger studies are required to establish concordance and clinical utility.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fruro.2026.1789586","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T05:59:50Z","timestamp":1775800790000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Liquid-based genomic profiling in high-risk localized prostate cancer"],"prefix":"10.3389","volume":"6","author":[{"given":"Fabiana","family":"Bettoni","sequence":"first","affiliation":[{"name":"Hospital S\u00edrio-Liban\u00eas","place":["S\u00e3o Paulo, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elis\u00e2ngela Monteiro","family":"Coser","sequence":"additional","affiliation":[{"name":"Hospital S\u00edrio-Liban\u00eas","place":["S\u00e3o Paulo, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernande Xavier","family":"dos Santos","sequence":"additional","affiliation":[{"name":"Hospital S\u00edrio-Liban\u00eas","place":["S\u00e3o Paulo, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda Rafaela Alves","family":"Canteli","sequence":"additional","affiliation":[{"name":"Hospital S\u00edrio-Liban\u00eas","place":["S\u00e3o Paulo, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romualdo","family":"Morandi Filho","sequence":"additional","affiliation":[{"name":"Hospital S\u00edrio-Liban\u00eas","place":["S\u00e3o Paulo, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vandecl\u00e9cio","family":"Lira","sequence":"additional","affiliation":[{"name":"Hospital S\u00edrio-Liban\u00eas","place":["S\u00e3o Paulo, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livia","family":"Loureiro","sequence":"additional","affiliation":[{"name":"Illumina, Inc.","place":["San Diego, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcia","family":"Dellamano","sequence":"additional","affiliation":[{"name":"Illumina, Inc.","place":["San Diego, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul","family":"Torrieri","sequence":"additional","affiliation":[{"name":"Illumina, Inc.","place":["San Diego, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jos\u00e9 Ferreira","family":"Alves","sequence":"additional","affiliation":[{"name":"Instituto do C\u00e2ncer do Estado de S\u00e3o Paulo","place":["S\u00e3o Paulo, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Cardili","sequence":"additional","affiliation":[{"name":"Instituto do C\u00e2ncer do Estado de S\u00e3o Paulo","place":["S\u00e3o Paulo, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Queiroz Borges","family":"Muniz","sequence":"additional","affiliation":[{"name":"Hospital S\u00edrio-Liban\u00eas","place":["S\u00e3o Paulo, Brazil"]},{"name":"Instituto do C\u00e2ncer do Estado de S\u00e3o Paulo","place":["S\u00e3o Paulo, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9der Nisi","family":"Il\u00e1rio","sequence":"additional","affiliation":[{"name":"Instituto do C\u00e2ncer do Estado de S\u00e3o Paulo","place":["S\u00e3o Paulo, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Chammas","sequence":"additional","affiliation":[{"name":"Instituto do C\u00e2ncer do Estado de S\u00e3o Paulo","place":["S\u00e3o Paulo, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William Carlos","family":"Nahas","sequence":"additional","affiliation":[{"name":"Hospital S\u00edrio-Liban\u00eas","place":["S\u00e3o Paulo, Brazil"]},{"name":"Instituto do C\u00e2ncer do Estado de S\u00e3o Paulo","place":["S\u00e3o Paulo, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diogo Assed","family":"Bastos","sequence":"additional","affiliation":[{"name":"Hospital S\u00edrio-Liban\u00eas","place":["S\u00e3o Paulo, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anamaria Aranha","family":"Camargo","sequence":"additional","affiliation":[{"name":"Hospital S\u00edrio-Liban\u00eas","place":["S\u00e3o Paulo, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2024.11.008","article-title":"Circulating tumor DNA: A new research frontier in urological oncology from localized to metastatic disease","volume":"8","author":"Garofoli","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1038\/s41467-021-23394-4","article-title":"Cell-free DNA captures tumor heterogeneity and driver alterations in rapid autopsies with pre-treated metastatic cancer","volume":"12","author":"Pereira","year":"2021","journal-title":"Nat Commun"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA: A Cancer J Clin"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.0228","article-title":"Prostate cancer: A review","volume":"333","author":"Raychaudhuri","year":"2025","journal-title":"JAMA"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac181","article-title":"Real-world comprehensive genomic profiling success rates in tissue and liquid prostate carcinoma specimens","volume":"27","author":"Hiemenz","year":"2022","journal-title":"Oncologist"},{"key":"B6","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12943-022-01543-7","article-title":"Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments","volume":"21","author":"Lone","year":"2022","journal-title":"Mol Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexmp.2017.11.011","article-title":"A straightforward assay to evaluate DNA integrity and optimize next-generation sequencing for clinical diagnosis in oncology","volume":"103","author":"Bettoni","year":"2017","journal-title":"Exp Mol Pathol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1038\/s41467-022-28648-3","article-title":"Whole-genome sequencing of 1, 171 elderly admixed individuals from Brazil","volume":"13","author":"Naslavsky","year":"2022","journal-title":"Nat Commun"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02768","article-title":"Molecular biomarkers in localized prostate cancer: ASCO guideline","volume":"38","author":"Eggener","year":"2020","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e2351700","DOI":"10.1001\/jamanetworkopen.2023.51700","article-title":"Concurrent tissue and circulating tumor DNA molecular profiling to detect guideline-based targeted mutations in a multicancer cohort","volume":"7","author":"Iams","year":"2024","journal-title":"JAMA Netw Open"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.10.025","article-title":"The molecular taxonomy of primary prostate cancer","volume":"163","author":"Abeshouse","year":"2015","journal-title":"Cell"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.03.029","article-title":"The evolutionary landscape of localized prostate cancers drives clinical aggression","volume":"173","author":"Espiritu","year":"2018","journal-title":"Cell"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/PO.19.00176","article-title":"Low abundance of circulating tumor DNA in localized prostate cancer","volume":"3","author":"Hennigan","year":"2019","journal-title":"JCO Precis Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13073-020-00770-1","article-title":"Detection of ctDNA in plasma of patients with clinically localized prostate cancer is associated with rapid disease progression","volume":"12","author":"Lau","year":"2020","journal-title":"Genome Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-024-06698-7","article-title":"Comparison of discovery rates and prognostic utility of [68Ga]Ga-PSMA-11 PET\/CT and circulating tumor DNA in prostate cancer\u2014a cross-sectional study","volume":"51","author":"Kluge","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B16","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1001\/jamasurg.2023.5394","article-title":"Applications of liquid biopsy for surgical patients with cancer: A review","volume":"159","author":"Mahuron","year":"2024","journal-title":"JAMA Surg"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15102702","article-title":"Liquid biopsy in early-stage lung cancer: current and future clinical applications","volume":"15","author":"Vandekerckhove","year":"2023","journal-title":"Cancers"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx118","article-title":"Concordance of circulating tumor DNA and matched metastatic tissue biopsy in prostate cancer","volume":"109","author":"Wyatt","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33865","article-title":"Contrasting genomic profiles from metastatic sites, primary tumors, and liquid biopsies of advanced prostate cancer","volume":"127","author":"Necchi","year":"2021","journal-title":"Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.19.00752","article-title":"Molecular biomarkers in localized prostate cancer: ASCO guideline summary","volume":"16","author":"Eggener","year":"2020","journal-title":"JCO Oncol Pract"}],"container-title":["Frontiers in Urology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fruro.2026.1789586\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T05:59:51Z","timestamp":1775800791000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fruro.2026.1789586\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":20,"alternative-id":["10.3389\/fruro.2026.1789586"],"URL":"https:\/\/doi.org\/10.3389\/fruro.2026.1789586","relation":{},"ISSN":["2673-9828"],"issn-type":[{"value":"2673-9828","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"article-number":"1789586"}}